Use Biologic Agents to Induce Remission in Patients with Moderately Severe Crohn’s Disease
New American Gastroenterological Association Guidelines Provide Guidance on Most Effective Treatment Pathway
Bethesda, MD (Dec. 17, 2013)
— The anti-TNF-α biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn’s disease, according to a new guideline from the American Gastroenterological Association (AGA). Additionally, the guidelines recommend against using thiopurines or methotrexate alone to induce remission in these patients. The new guideline1
and accompanying technical review2
have been published in Gastroenterology
, the official journal of the AGA Institute. The AGA Clinical Decision Support Tool, based on the guideline, can be reviewed at http://gastro.org/crohnsdecisiontool
“Crohn’s disease is a lifelong, relapsing disorder that can damage the bowel and lead to multiple abdominal operations over time. Deciding which medications are the best is a common dilemma for gastroenterologists and the Crohn’s patients we treat. The disease can be disabling, but the drugs to control the disease can be toxic too and they can be costly. Balancing the benefits and the risks of the drugs and determining which medicines are most likely to keep the patient healthy is critical,” according to Jonathan P. Terdiman, MD, lead author of the guidelines, and Chief of the Gastroenterology Service at the University of California, San Francisco Medical Center. “The new AGA guideline and clinical decision support tool will ease the decision process by providing transparent and actionable recommendations.”
Crohn’s disease is a chronic inflammatory bowel disease that causes significant morbidity and represents a considerable burden to society. It is estimated that 300,000 to 500,000 Americans suffer from Crohn’s disease, costing the health-care system between $2.5 and $4 billion per year.
These guidelines are the first to make medication recommendations based on methodology that includes review of risks and benefits, patient preferences, and the quality of clinical evidence.
For the induction of remission, the guidelines recommend:
Using anti-TNF-α drugs to induce remission in patients with moderately severe Crohn’s disease (strong recommendation, moderate-quality evidence).
Using anti-TNF-α monotherapy over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn’s disease (strong recommendation, moderate-quality evidence).
Using anti-TNF-α drugs in combination with thiopurines over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn’s disease (strong recommendation, high-quality evidence).
For maintenance of remission, the guidelines recommend:
Using thiopurines over no immunomodulator therapy to maintain a steroid-induced remission in patients with Crohn’s disease (strong recommendation, moderate-quality evidence).
Using anti-TNF-α drugs over no anti-TNF-α drugs to maintain a steroid or anti-TNF-α drug-induced remission in patients with Crohn’s disease (strong recommendation, high-quality evidence).
This guideline is AGA’s first to practice AGA's new clinical guideline development process that employs the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. GRADE has been adopted by several national and international societies, including the AGA, and is becoming the common methodology for the streamlined and rigorous development of clear, transparent and actionable guidelines.
About the AGA Institute
The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to include 17,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. www.gastro.org
, the official journal of the AGA Institute, is the most prominent scientific journal in the specialty and is in the top 1 percent of indexed medical journals internationally. The journal publishes clinical and basic science studies of all aspects of the digestive system, including the liver and pancreas, as well as nutrition. The journal is abstracted and indexed in Biological Abstracts, Current Awareness in Biological Sciences, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index. For more information, visit www.gastrojournal.org
1 out of 1 users found this page helpful.
Was this page helpful?